News

Cambrex Wins API Development Award at CPhI Worldwide

October 17, 2016

East Rutherford, NJ – 17th October, 2016 – Cambrex Corporation (NYSE: CBM) the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has won the ‘API Development’ category at the annual CPhI Pharma Awards, which took place at a Gala Dinner at CPhI Worldwide in Barcelona on October 4th.

The winning entry presented a case study which examined Cambrex’s synthesis to an intermediate of Dronedarone. The approach taken by Cambrex saw the development of a novel route with significant economic and environmental benefits, while maintaining quality and regulatory requirements.

“This award is a great recognition of the experience and technical expertise of our team, not only in terms of innovation, but also in recognition of our ability to turn innovative ideas into a commercialized process” commented Jonathan Knight, Vice President, New Product Development. He added, “We would like to thank our industry peers and editors who make up the judging panel for acknowledging the innovative approach that we employed when faced with certain production issues.”

Established in 2004, the CPhI Pharma Awards are among the most prestigious recognitions within the pharmaceutical industry. The awards celebrate thinkers and creators breaking new ground and strongly advocate companies committed to driving the industry forward.

About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com